A	B	C	D
1	Main
2		Brand Name	LY2140023
3		Generic Name	pomaglumetad methionil
4		Indication	Schizophrenia
5		Mechanism	Acts on mGlu2/3 protein in the brain
6		Clinical Trials
7			Phase II vs Zyprexa vs placebo n=196
8			PANSS versus placebo: -20.8 for LY2140023 and -26.7 for Zyprexa.
9			Response rate 32.0% for LY2140023 and 41.2% for placebo.
10
11			Sept 2007 - Jan 2009
12			4 weeks
13				160mg, 2x80mg per day
14
15			Potential seizures, LLY is conducting monkey tox studies to determine if Phase III is warranted.